TTRX logo

TTRX
Turn Therapeutics Inc

384
Mkt Cap
$141.79M
Volume
112,377.00
52W High
$26.50
52W Low
$2.57
PE Ratio
-26.20
TTRX Fundamentals
Price
$4.97
Prev Close
$4.76
Open
$4.77
50D MA
$3.62
Beta
1.22
Avg. Volume
27,805.49
EPS (Annual)
-$0.1152
P/B
23.18
Rev/Employee
$0.00
$104.21
Loading...
Loading...
News
all
press releases
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M...
Business Wire·3d ago
News Placeholder
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial...
Business Wire·10d ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy?
Turn Therapeutics (NASDAQ:TTRX) Shares Up 6% - Here's Why...
MarketBeat·27d ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results
Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter...
MarketBeat·2mo ago
News Placeholder
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results...
Business Wire·2mo ago
News Placeholder
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX)
D. Boral Capital restated a "buy" rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday...
MarketBeat·2mo ago
News Placeholder
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan...
Business Wire·2mo ago
News Placeholder
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
Turn Therapeutics (NASDAQ:TTRX) executives outlined the company's focus on inflammatory skin disease and provided updates on its lead topical candidate, GX-03, during a presentation at an...
MarketBeat·3mo ago
News Placeholder
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment...
Business Wire·3mo ago
<
1
2
...
>

Latest TTRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.